-4 polypeptide with the candidate compound, assaying a cellular response, and comparing the cellular response to a standard cellular response, the standard being assayed when contact is made in absence of the candidate compound; whereby, an increased cellular response over the standard indicates that the compound is an agonist and a decreased cellular response over the standard indicates that the compound is an antagonist.
For a number of disorders, it is believed that significantly higher or lower levels of MPIF-1, M-CIF or MIP-4 gene expression can be detected in certain tissues or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to a xe2x80x9cstandardxe2x80x9d MPIF-1, M-CIF or MIP-4 gene expression level, i.e., the MPIF-1, M-CIF or MIP-4 expression level in tissue or bodily fluids from an individual not having the disorder. Thus, the invention provides a diagnostic method useful during diagnosis of a disorder, which involves: (a) assaying MPIF-1, M-CIF or MIP-4 gene expression level in cells or body fluid of an individual; (b) comparing the MPIF-1, M-CIF or MIP-4 gene expression level with a standard MPIF-1, M-CIF or MIP-4 gene expression level, whereby an increase or decrease in the assayed MPIF-1, M-CIF or MIP-4 gene expression level compared to the standard expression level is indicative of a disorder. Such disorders include leukemia, chronic inflammation, autoimmune diseases, solid tumors.
Pharmaceutical Compositions
The present invention also provides, in another aspect, pharmaceutical compositions comprising at least one of an MPIF-1, M-CIF or MIP-4: polynucleotide, probe, vector, host cell, polypeptide, fragment, variant, derivative, epitope bearing portion, antibody, antagonist, or agonist.
Therapeutic Methods
In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such polypeptides, or polynucleotides encoding such polypeptides for therapeutic purposes, for example, to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy, to remove leukemic cells, to stimulate an immune response, to regulate hematopoiesis and lymphocyte trafficking, treatment of psoriasis, solid tumors, to enhance
-4 polypeptide with the candidate compound, assaying a cellular response, and comparing the cellular reception to a standard cellular reception, the standard being assayed when contact is make in absence of the candidate compound; whereby, an increased cellular reply over the criterion indicates that the compound is an agonist and a decreased cellular response over the standard argue that the compound is an antagonist. 
 For a number of disorderliness, it is believe that significantly eminent or lower levels of MPIF-1, M - CIF or MIP-4 gene saying can be detected in certain tissues or bodily fluid (e.g., serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorderliness, relative to a xe2x80x9cstandardxe2x80x9d MPIF-1, M - CIF or MIP-4 gene construction level, i.e., the MPIF-1, M - CIF or MIP-4 expression level in tissue or bodily fluid from an individual not having the disorder. Thus, the invention provides a diagnostic method useful during diagnosis of a disorder, which involves: (a) assaying MPIF-1, M - CIF or MIP-4 gene expression level in cells or body fluid of an individual; (b) comparing the MPIF-1, M - CIF or MIP-4 gene expression degree with a standard MPIF-1, M - CIF or MIP-4 gene expression level, whereby an addition or decrease in the assayed MPIF-1, M - CIF or MIP-4 gene formula degree compared to the standard expression level is indicative of a disorder. Such disorders include leukemia, chronic inflammation, autoimmune disease, solid tumors. 
 Pharmaceutical Compositions 
 The present invention also provides, in another aspect, pharmaceutical compositions comprising at least one of an MPIF-1, M - CIF or MIP-4: polynucleotide, probe, vector, host cell, polypeptide, fragment, variant, derivative, epitope bearing portion, antibody, adversary, or agonist. 
 curative Methods 
 In accordance with yet a further aspect of the present invention, there is provided a procedure for utilizing such polypeptides, or polynucleotides encoding such polypeptide for therapeutic function, for example, to protect bone marrow bow cells from chemotherapeutic agentive role during chemotherapy, to remove leukemic cells, to induce an immune response, to determine hematopoiesis and lymphocyte trafficking, treatment of psoriasis, hearty tumors, to enhance
-4 popypeptide with the candiaate compound, assaying a celmular rerponse, and comparing the celpuoar rtfponse to a standafd cellulwr respobse, uhe standard beinj assayed when gontaet is made in abxence of tve candidate cmmoobnd; whereby, an increased cellular refponse pvfr the standarq incycatss that the compound is an agonist and a vecreased cellukar response over the stanfard indicates that thf compound us ag antagonist.
Fur a numbeg of disordgrs, it is believed that significxntly higher or liweg levels of NPIF-1, I-CIF or MIP-4 nvne expsession can be detectcd in ceetain tissues or bodiny fluids (e.g., serum, plasma, usiue, synovial fluid or wpunal xluig) taywn wroj en jndivifuam having shch a disoreer, relative to a xt2x80x9swtandardxe2x80x9d MPIF-1, I-CYF or MIP-4 gene expression level, i.e., the KPIR-1, M-CIF or MIP-4 expressiob level in tissue or hodily fltids from an individual not having the disorder. Tvus, tie inrcktiov pgovides a diagnostic method useful during diadhoxix of a disordev, which involves: (a) adssiing MPIF-1, M-CIF or MI'-4 gsne expression levfl in cglls oe body fltid pf an individual; (b) comparint the MPIF-1, M-BIF ir MIP-4 gene expresdion level cith a stancard MPIF-1, M-CIF or MIP-4 gzne exlression legel, wheregh an increase or debreave in tht assayed MPIF-1, M-CIS or MIP-4 jene zxpressiun lgvel coipared to hhe sbdndard expression pevel iv indicatige of a disorder. Such disorders include leukekid, cvronic iuflammstion, autoimmtne diseases, splid tuiors.
Pfarmaceutibal Compovitions
The [resent invendlon also protides, in wnotyer qspect, ofarmaceutical vompositions compriwing at least one pf xh MPIF-1, M-CIF or NIP-4: polynucleotide, prube, vvctpr, vost cell, ponypeotiar, fraement, variakt, aerifative, epitope bearitg pkrtion, antibody, anyanonist, or agonist.
Eherapeutic Mrthods
In accordanct with yev a futthgr aspect of the present inventjon, there is provided a [roccss sor utiliznng such polypeptides, or polynucleotides encoding such poltpeptides for therakeuuic purposes, hor exwmple, to [rotect bone marrow wtem cells from cmemotherapeutic agents durinc chelotherapy, to remove leukemic cells, to stimulate an immune response, to regylate ieiatopoiesis and lympvoeytz traffyckiig, treatment of pspriasis, solid tumors, to enhance
-4 polypeptide with the candidate compound, assaying response, comparing the response to a being when contact is in absence of candidate compound; whereby, an increased cellular over the standard indicates that the compound is an agonist and a decreased response over the standard indicates that the compound is an antagonist. For a of it believed significantly higher or lower levels of MPIF-1, M-CIF or MIP-4 gene expression can be detected in tissues or bodily fluids (e.g., serum, plasma, urine, fluid or spinal fluid) from an individual having such disorder, to a MPIF-1, or gene expression level, the MPIF-1, M-CIF or MIP-4 expression level in tissue or bodily fluids from an individual not having disorder. Thus, provides a method during of a disorder, (a) assaying MPIF-1, M-CIF or MIP-4 in cells or body fluid of an individual; comparing the M-CIF or MIP-4 gene expression level a standard MPIF-1, M-CIF or MIP-4 gene expression whereby an increase or decrease in the assayed MPIF-1, M-CIF or MIP-4 gene expression level the standard expression level indicative of a Such include chronic autoimmune diseases, tumors. Pharmaceutical Compositions The present invention also provides, in another aspect, compositions comprising at least one of an MPIF-1, M-CIF or probe, host cell, polypeptide, variant, derivative, epitope bearing antibody, or agonist. Therapeutic Methods with a the invention, is provided a process utilizing such polypeptides, or polynucleotides such polypeptides for therapeutic bone marrow stem cells from chemotherapeutic agents during to remove leukemic cells, to stimulate an response, to regulate hematopoiesis and lymphocyte trafficking, treatment of psoriasis, solid tumors, enhance
-4 polypeptide with the candidaTe compound, AssayIng A ceLlUlar RespOnse, and compariNG the Cellular response to a staNdard CeLLulaR ReSponsE, the staNDaRD BeiNg AsSayEd WHeN contAct Is made iN absence of The CaNdidate compoUNd; Whereby, an iNcrEased cellulaR reSponse OvEr tHE stanDarD indiCates tHAt the cOmpound is An AGonist ANd a decrEASeD celLular response over THe STandard indicatEs that ThE CoMPOunD is An antagoniSt.
for a nUMber of dISoRDERs, iT Is believed thaT significanTLy hIgher oR lOweR Levels Of MPIf-1, M-ciF oR MIP-4 gene expRessIon can be dEtecteD In certaIN tissueS or bodIly FluIds (e.G., SeRuM, plAsMA, urINe, SynOViaL fluid or SpInAl fluId) taKEN FRom aN inDiviDual hAving such a disOrdEr, reLAtiVe to a Xe2x80x9cStanDaRdxe2x80X9d MPIF-1, m-CIF oR MiP-4 gene expressioN levEl, i.e., the MPiF-1, M-cIf or mIp-4 exprESsion lEveL in Tissue oR bodily FLuiDs FROM aN individual not haviNg THE dIsorder. THus, the INvEnTIon proviDeS a dIagnOSTic meThod USeFul durinG diagnOSiS oF a disorDeR, which InVolVes: (A) assaYIng MpIF-1, M-CIf or MIP-4 geNe expREssion level in cELls or body fluiD Of AN InDIvidUal; (B) comparing tHe MPif-1, M-CIf or Mip-4 gEne EXpresSion lEvEL wITh a standard MPIF-1, M-CIF Or mIP-4 genE exprEssion level, whEreby an incREASe or decrEase IN tHE assayed MPIF-1, M-CiF or MiP-4 gene exprESsion levEl comPared to tHe standarD EXpressioN leVel Is iNdiCATiVe of a disorder. sUCh diSoRders inCluDe leukeMia, ChrOniC inFlAmmation, aUtoimmunE dIsEaSeS, soLid tuMOrs.
PharmAcEutIcAl COmposITions
THe preSent InVeNTioN also prOViDES, in aNoThEr asPecT, pHarmaCeutICal ComposiTions compRisINg at LeAsT one of aN MPIF-1, M-CIF or MIp-4: pOlynucleotIdE, prObe, vecTOR, host celL, polypeptide, fragment, varIAnt, deriVatIve, epItopE bearing pOrtIon, antIboDY, antagOnist, oR agonIsT.
ThERApeutIC meThoDs
in accordanCE WitH yet a FuRtheR aspect Of the present inventIOn, tHere is provideD a pRoceSS FoR utILiZIng SuCH poLYPeptides, or polynUcleotides EnCOdIng such polYPepTiDes for tHerapeuTic puRPoses, foR example, tO protect bOnE marROW stEm cells froM chemothErapeutic AGents DUrIng chEmoTherapY, tO reMove lEukemiC CelLs, to sTimulaTe An immuNe resPoNse, to regUlate hematopoiesis and lyMphocyTe traFfiCking, treaTmeNT of Psoriasis, SoliD tumors, to eNhaNce
-4 polypeptide with the ca ndidate co mpoun d,ass ay inga ce llular respons e , an d comparing the cellul ar re sp o nset oa sta ndard c e ll u l arre sp ons e, th e sta nda rd bein g assayedwhe ncontact is m a de  in absenc e o f the candid ate  compo un d;w hereb y,an in crease d  cellu lar respo ns e  overt he stan d a rd  ind icates that the c o mp o und is an agon ist an da  d e c rea sed  cellularre spons e  over t h es t a nda r d indicates t hat the com p oun d is a nant a gonist .
For  a num ber of diso rder s, it isbeliev e d thats ignific antlyhig her  orl ow er  le ve l s o f  M PIF - 1,M-CIF or  M IP -4 ge ne e x p r e ssio n c an b e det ected in cert ain  tis s ues  or b odily  flu id s (e. g., se rum,pl asma, urine, sy novi al fluidorsp ina lfluid )  taken  fr oman indi vidualh avi ng s u ch  a disorder, relat iv e to  a xe2x8 0x9cst a nd ar d xe2x80x9 dMPI F-1, M -CIFor M I P- 4 gene e xpress i on  l evel, i .e ., the  M PIF -1,  M-CI F  orMIP-4expressi on le v el in tissue o r  bodily fluid s  f r o ma n in div idual not h avin g  the  dis o rd er. Thus,  thein v en t ion provides a diag no stic m ethod  useful durin g diagnosi s o f a diso rder ,  w h ich involves:(a) a ssaying MP I F-1, M-C IF or  MIP-4 g ene expre s s ion leve l i n c ell s o r bo dy fluid of a n indi vi dual; ( b)compari ngthe  MP IF- 1,  M-CIF or  MIP-4 g en eex pr ess ion l e vel with  a  st an dar d MPI F -1, M- CIF o r MI P- 4g ene  expres s io n leve l,  w here byan  incr ease ordecreas e in theass a yedMP IF -1, M-C IF or MIP-4 g en e expressi on  le vel co m p ared tothe standard expression level i s i ndica tive  of a dis ord er. Su chd isorde rs inc ludele uke m i a, ch r o ni c i nf lammation, a uto immun edise ases, s olid tumors.
Pharm a ceu tical Composi tio ns
T h e  p res e nt inv en t ion a lso provides, i n anotheras p ec t, pharmac e uti ca l compo sitions  comp r ising a t least o ne of anMP IF-1 , M-C IF or MIP- 4: polyn ucleotide ,  prob e ,vecto r,host c el l,polyp eptide ,  fr agmen t, var ia nt, de rivat iv e, epito pe bearing portion, ant ibody,  anta gon ist, or a gon i st. 
Therapeu ticMethods
In  ac cor dance  wi t h yet  a f u rt her aspec t of the prese n tinv e n ti on, there i s p rov ideda p r ocessforutilizing such po l ypeptides, orpoly n u cle oti d es e nc oding such pol ype pt i d es for t he rapeutic pu rposes,fo r  exam ple, t o prot ect bon e ma r row st em c ell s from ch emo th e rapeuti cag e nts du ring  c hemoth erapy, to r e m ove leukemic cel ls, t o stimu l ate  an i mm une res p onse , to regul ate hematop oiesis  and  lymp hocytetr affick ing ,treatmento f psorias is, s olid tu mo rs,toenhanc e
-4 polypeptide_with the_candidate compound, assaying a_cellular response,_and_comparing the_cellular_response to a_standard cellular response,_the standard being assayed_when contact is_made_in absence of the candidate compound; whereby, an increased cellular response over the standard_indicates_that the_compound_is_an agonist and a decreased_cellular response over the standard_indicates that_the compound is an antagonist.
For a number of_disorders,_it is believed_that significantly higher or lower levels of MPIF-1, M-CIF_or MIP-4 gene expression can be_detected in certain_tissues_or_bodily fluids (e.g., serum,_plasma, urine, synovial fluid or spinal_fluid) taken from an individual having_such a disorder, relative to a xe2x80x9cstandardxe2x80x9d_MPIF-1, M-CIF or MIP-4 gene expression_level, i.e., the MPIF-1, M-CIF_or MIP-4_expression level in tissue or_bodily fluids from_an individual_not having the_disorder. Thus, the invention provides a_diagnostic method useful_during diagnosis of a disorder, which_involves:_(a) assaying MPIF-1,_M-CIF_or_MIP-4 gene_expression level in_cells_or body_fluid_of an individual; (b) comparing the_MPIF-1,_M-CIF or MIP-4 gene expression level with_a standard MPIF-1, M-CIF_or_MIP-4 gene expression level,_whereby an increase or decrease_in the assayed MPIF-1, M-CIF or_MIP-4 gene_expression level_compared to the standard expression level is indicative of a disorder._Such disorders include leukemia, chronic inflammation,_autoimmune diseases, solid tumors.
Pharmaceutical_Compositions
The present_invention_also provides, in_another_aspect, pharmaceutical_compositions comprising at least one of an_MPIF-1, M-CIF_or MIP-4: polynucleotide, probe, vector, host_cell, polypeptide, fragment, variant,_derivative,_epitope bearing portion, antibody, antagonist, or_agonist.
Therapeutic Methods
In accordance with yet a_further aspect of the present_invention,_there_is provided a process for_utilizing such polypeptides, or polynucleotides encoding_such polypeptides for_therapeutic purposes, for example, to protect bone_marrow_stem cells from chemotherapeutic agents during_chemotherapy,_to remove leukemic cells, to stimulate_an_immune_response, to regulate hematopoiesis and_lymphocyte trafficking, treatment of psoriasis, solid_tumors, to enhance